Nivolumab

Nivolumab is a monoclonal antibody medication used for the treatment of various types of cancer. It works by targeting a protein called PD-1, which is found on the surface of immune system cells called T-cells. By blocking the interaction between PD-1 and its ligands, Nivolumab helps to enhance the body’s immune response against cancer cells.
Nivolumab is approved for the treatment of several cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodgkin lymphoma. It is often used as a targeted therapy, meaning it specifically targets cancer cells while minimizing damage to healthy cells. This targeted approach can lead to fewer side effects compared to traditional chemotherapy treatments.
The use of Nivolumab is determined by a patient’s individual cancer type, stage, and overall health. It is typically administered through intravenous infusion and is often used in combination with other cancer treatments, such as chemotherapy or radiation therapy.
In clinical trials, Nivolumab has demonstrated significant efficacy in prolonging survival and improving the quality of life for patients with advanced cancers. However, like all medications, it may cause side effects, which can include skin reactions, fatigue, and gastrointestinal issues. It is essential for patients to discuss the potential benefits and risks of Nivolumab with their healthcare provider before starting treatment.